BioVie Inc. (BIVI) Prices 1.15M Share Offering at $2.83/sh

BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.

The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock are being offered by the Company.

The registered direct offering is expected to close on or about October 29, 2024, subject to the satisfaction of customary closing conditions.

ThinkEquity is acting as sole placement agent for the offering.

The securities were offered and will be sold pursuant to a shelf registration statement on Form S-3 (File No. 333-274083), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 18, 2023 and declared effective on August 28, 2023. The offering will be made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Aeva Technologies launches $100 million follow-on stock offering
• SpaceX files for 555.56M share IPO at $135/sh
• FG Merger II sets stockholder vote on BOXABL merger for June 9